KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Finished Goods (2016 - 2019)

Jazz Pharmaceuticals (JAZZ) has 10 years of Finished Goods data on record, last reported at $22.3 million in Q1 2019.

  • For Q1 2019, Finished Goods changed N/A year-over-year to $22.3 million; the TTM value through Mar 2019 reached $22.3 million, changed N/A, while the annual FY2018 figure was $21.3 million, 11.22% down from the prior year.
  • Finished Goods reached $22.3 million in Q1 2019 per JAZZ's latest filing, up from $21.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $24.0 million in Q4 2017 and bottomed at $5.0 million in Q4 2015.
  • Average Finished Goods over 5 years is $16.0 million, with a median of $17.9 million recorded in 2018.
  • Peak YoY movement for Finished Goods: plummeted 69.83% in 2015, then soared 175.91% in 2016.
  • A 5-year view of Finished Goods shows it stood at $5.0 million in 2015, then skyrocketed by 175.91% to $13.8 million in 2016, then surged by 73.8% to $24.0 million in 2017, then dropped by 11.22% to $21.3 million in 2018, then rose by 4.68% to $22.3 million in 2019.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $22.3 million in Q1 2019, $21.3 million in Q4 2018, and $17.9 million in Q2 2018.